Business Context and Reporting Period
This Form 8-K Current Report was filed by Ultragenyx Pharmaceutical Inc. on March 3, 2020. The filing discloses the voluntary resignation of Shalini Sharp, the Company's Executive Vice President and Chief Financial Officer, effective upon the earlier of her successor's start date or September 2, 2020.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and transition terms.
- Current Annual Base Salary: $501,900
- Transition Period Annual Base Salary: $380,000
- Equity Vesting: Existing options, RSUs, and PSUs continue to vest during the transition period.
- Equity Exercise Window: Vested awards remain exercisable for 120 days after the Separation Date.
Material Changes
The primary material change is the departure of the Chief Financial Officer. Ms. Sharp cited personal reasons and a desire to focus on family and advisory roles as the cause. The Company has initiated a search for a successor. During the transition period, Ms. Sharp's duties will be limited to knowledge transfer and project assistance, with a reduction in base salary.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. The primary risk disclosed is the operational impact of the CFO vacancy and the associated transition period. Ms. Sharp remains eligible for her 2020 annual cash incentive bonus, contingent on corporate performance goals.
Investor Verification Checklist
- Confirm the timeline for the appointment of a new Chief Financial Officer.
- Review the full text of the Transition Letter Agreement (Exhibit 10.1) for additional severance or liability terms.
- Monitor subsequent filings for the announcement of the successor CFO.
- Verify the impact of the CFO transition on the Company's upcoming financial reporting cycle.